ACR/VF Treatment Guidelines
2021 American College of Rheumatology/Vasculitis Foundation Guidelines
These guidelines present the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of:
- ANCA–associated vasculitides: Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA), and Eosinophilic granulomatosis with polyangiitis (EGPA)
- Polyarteritis nodosa (PAN)
- Giant Cell Arteritis and Takayasu Arteritis
- Kawasaki Disease (KD)
These recommendations provide guidance regarding the evaluation and management of patients, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
ANCA-Associated Vasculitis (GPA/MPA/EGPA) Guidelines
The American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Polyarteritis Nodosa (PAN) Guidelines
These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
Giant Cell Arteritis (GCA) & Takayasu Arteritis (TAK) Guidelines
These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
Kawasaki Disease (KD) Guidelines
These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with KD.
![Logo for Vasculitis Awareness Month (VAM), observed in May. The logo features bold letters 'VAM [may]' with the words 'Vasculitis Awareness Month' beneath, and a stylized circular symbol composed of overlapping white rings to the left.](https://vasculitisfoundation.org/wp-content/uploads/2025/04/VAM-logo-All-White-1024x349.png){kind=logo}